# John McManus

> John L. McManus is a California-based biotechnology executive whose career joins finance, company strategy and national preparedness. Now President, Health Security at Partner Therapeutics, he has spent more than 15 years working on medical countermeasures and, according to the company, has obtained and managed more than $500 million in procurement and development contracts. His earlier work included leading Aeolus Pharmaceuticals, advising public-company management teams and boards, and serving in strategic and financial roles at Spectrum Pharmaceuticals and NeoTherapeutics.

- **Role:** President, Health Security at Partner Therapeutics
- **Organizations:** Partner Therapeutics, Aeolus Pharmaceuticals, McManus Financial Consultants, Spectrum Pharmaceuticals, NeoTherapeutics, University of Southern California
- **Education:** B.S. in International Finance and Business Economics, University of Southern California
- **Known for:** Has obtained and managed more than $500 million in procurement and development contracts during more than 15 years in health security, according to Partner Therapeutics., Managed a BARDA contract worth more than $100 million while serving as CEO of Aeolus Pharmaceuticals., Led strategic and financial restructuring work at Spectrum Pharmaceuticals; an Aeolus SEC filing credited the implementation with increasing Spectrum's market value from $1 million to more than $125 million by his departure.

## Career timeline

- **1989-2020** — Led McManus Financial Consultants, advising public-company executives and boards on strategy, finance, investor relations, and mergers and acquisitions.
- **2001-2003** — Served as Vice President, Finance and Strategic Planning at Spectrum Pharmaceuticals, with responsibility for restructuring operations and finances.
- **2005** — Joined Aeolus Pharmaceuticals as a consultant and president.
- **2006** — Became Aeolus's President and Chief Operating Officer.
- **2007-2018** — Served as President and Chief Executive Officer of Aeolus Pharmaceuticals, focusing on health security and respiratory programs.
- **2011** — Aeolus received a BARDA contract worth up to $118 million for advanced development of a radiation medical countermeasure.
- **2019** — Joined Partner Therapeutics as Chief Business Officer, overseeing business development and government relations.
- **2025-present** — Listed by Partner Therapeutics as President, Health Security.

## Achievements

- Has obtained and managed more than $500 million in procurement and development contracts during more than 15 years in health security, according to Partner Therapeutics.
- Managed a BARDA contract worth more than $100 million while serving as CEO of Aeolus Pharmaceuticals.
- Led strategic and financial restructuring work at Spectrum Pharmaceuticals; an Aeolus SEC filing credited the implementation with increasing Spectrum's market value from $1 million to more than $125 million by his departure.
- Helped extend Partner Therapeutics' government and development collaborations across radiological, chemical, biological and pandemic preparedness programs.
- Coauthored and contributed to scientific and preparedness presentations concerning medical countermeasures.

## Latest updates

- **2025-05** — Listed as a coauthor with Yale's Nicholas Dainiak on a ConRad 2025 conference abstract about radiation exposure, sepsis and military space operations.
- **2026-09** — Partner Therapeutics' leadership page lists McManus as President, Health Security and credits him with more than $500 million in procurement and development contracts.
- **2024-09** — Appeared as a Partner Therapeutics coauthor on a European radiation-research conference presentation concerning sargramostim in a total-body irradiation model.

## Links

- Website: https://www.partnertx.com/
- LinkedIn: https://www.linkedin.com/in/john-l-mcmanus-a4583a4

---

Profile page: https://yespress.io/john-mcmanus
Published by YesPress — https://yespress.io
Last updated: 2026-09-26